As expected, our results reflect additional investments behind our new launches and Alcon, we are on track with the plan we outlined in January to further focus our divisions, drive greater innovation and significant synergies and productivity. I remain confident in our long-term growth prospects.

Chief Executive Joe Jimenez

Categorized in : Healthcare

We would now think through that, and would potentially make a decision to exit without a premium, if the opportunity were right.

Chief Executive Joe Jimenez

business

We had to shift the culture of the company in terms of a complian... by Chief Executive Joe Jimenez

We had to shift the culture of the company in terms of a compliance standpoint.

Chief Executive Joe Jimenez

business

He's very ... agnostic as to where a technology rests, whether it's in academia or in another company or in our company, so you could see a much more open view of where we're going to source new technologies.

Chief Executive Joe Jimenez

company-news

The basic infrastructure of electronic medical records, let's call it 'real-world data', is going to have to increase so that we can easily track and monitor outcomes, if you move to that kind of pricing system over a period of years, you will be able to take out a lot of waste.

Chief Executive Joe Jimenez

company-news

It's not going to happen any time soon, but that's part of the solution, with an ageing population there's going to be additional pressure on pricing and total drug utilisation, particularly in the U.S.

Chief Executive Joe Jimenez

company-news

We have seen a bit of a slowdown in emerging markets particularly China but in our business that means moving from mid-double digit growth rates to now in the mid-single digit growth rates, if you think about the global healthcare market maybe growing at 2 or 3 percent this is still incremental growth.

Chief Executive Joe Jimenez

healthcare

So we are not pulling back. We're in these markets for the long term. We are going to live through the volatility, we have seen a bit of a slowdown in emerging markets particularly China but in our business that means moving from mid-double digit growth rates to now in the mid-single digit growth rates.

Chief Executive Joe Jimenez

health-news

We're looking at everything that's out there, the reason why Novartis hasn't moved is that assets are very expensive right now and I think we're going to hold our powder, we're going to see what happens in the markets.

Chief Executive Joe Jimenez

health-news

The average hospital stay for a heart failure patient in the United States is $11,000, so we are not receiving pushback on the price because I think this is seen as good value.

Chief Executive Joe Jimenez

company-news